Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience received a notice that a holder plans to sell 2,184 shares of its common stock on or about 02/13/2026. The shares, with an aggregate market value of $105,401.37, will be sold through Fidelity Brokerage Services LLC on the NASDAQ exchange.
The securities were acquired on 02/05/2026 via restricted stock vesting from the issuer as compensation. As of the filing, there were 61,311,704 common shares outstanding, which is a baseline figure and not the amount being sold.
Patrick Finn filed a notice to sell up to 3,500 shares of Twist Bioscience common stock under Rule 144. The filing lists an aggregate market value of 175,789.00 for these shares, to be sold through Fidelity Brokerage Services LLC on NASDAQ.
The shares come from option grants dated 11/19/2018 and 10/24/2019 totaling 2,500 shares, and 1,000 shares from restricted stock vesting on 11/08/2024. Recent activity also shows separate sales, including 23,279 shares on 01/13/2026 for gross proceeds of 931,160.00.
Adam Laponis filed a Form 144 indicating an intent to sell up to 7,000 shares of Twist Bioscience common stock. The planned sale through Fidelity Brokerage Services on NASDAQ has an aggregate market value of 350000.00. Twist Bioscience had 61,311,704 common shares outstanding.
The shares to be sold were acquired through restricted stock vesting from the issuer on 10/01/2025, 10/08/2025, and 10/29/2025, totaling 6,, , , , , 614, 2,170, and 4,216 shares as compensation.
Twist Bioscience Corp chief accounting officer Robert F. Werner reported a charitable stock gift. On 02/09/2026, he disposed of 2,000 shares of Twist Bioscience common stock in a bona fide gift to a charitable organization at a reported price of $0 per share.
Following this gift transfer, Werner directly beneficially owned 56,738 shares of Twist Bioscience common stock.
A shareholder of TWST plans to sell 5,000 shares of common stock through Fidelity Brokerage Services for an aggregate market value of $249,650.00, with an approximate sale date of February 11, 2026 on the NASDAQ exchange.
The filing notes that 61,311,704 shares of this class were outstanding. It also lists recent sales by Dennis H. Cho, including 1,099 common shares sold on February 3, 2026 for gross proceeds of $51,186.47, alongside three earlier sales in November and December 2025.
Twist Bioscience director Keith Crandell received an annual equity award of 5,095 shares of common stock on February 5, 2026 at a price of $0 per share. After this grant, he directly owns 27,571 shares of Twist Bioscience common stock.
These annual award shares will fully vest on the earlier of the one-year anniversary of the grant date or the first annual shareholder meeting after the grant, as long as he continues serving as a non‑employee director. In addition, 76,047 shares are held indirectly through the Keith L. Crandell Trust, for which he and his spouse are co‑trustees and he is the sole beneficiary.
Twist Bioscience director Melissa A. Starovasnik received an annual equity award of 5,095 shares of common stock on February 5, 2026. The shares were granted at a price of $0, increasing her directly held position to 26,722 shares after the transaction.
According to the award terms, 100% of these shares will vest on the earlier of one year from the grant date or the first annual stockholder meeting after the grant, as long as she continues to serve as a non-employee director on the applicable vesting date.
Twist Bioscience director Robert P. Ragusa received an annual stock award of 5,095 common shares on February 5, 2026. The shares were granted at a price of $0 per share, reflecting a typical equity compensation grant for a non-employee director.
According to the vesting terms, 100% of this annual equity award will vest on the earlier of one year from the grant date or the first annual stockholder meeting after the grant, as long as he continues serving as a director. Following this grant, Ragusa beneficially owns 28,983 Twist Bioscience common shares in total, held directly.
Twist Bioscience director Robert Chess reported a stock grant and updated his holdings. On February 5, 2026, he received an annual equity award of 5,095 shares of common stock at a price of $0 per share, increasing his directly held shares to 23,268.
The award vests in full on the earlier of one year from grant or the first stockholder meeting after the grant, so long as he continues as a service provider. He also beneficially owns 42,528 shares indirectly through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.
Twist Bioscience director Chan Nelson received an annual equity award of 5,095 shares of common stock on February 5, 2026. The award was granted at no cash cost per share and increased Nelson’s directly held stake to 33,251 shares.
The shares vest 100% on the earlier of the one-year anniversary of the grant date or the first annual stockholders’ meeting after the grant, as long as Nelson continues serving as a non-employee director on the applicable vesting date.